Clinical Consequences of Mutations in Thyroid Hormone Receptor-α1.
Thyroid hormone (TH) exerts its biological activity via the TH receptors TRα1 and TRβ1/2, which are encoded by the THRA and THRB genes. The first patients with mutations in THRB were identified decades ago. These patients had a clinical syndrome of resistance to TH associated with high serum TH and nonsuppressed thyroid-stimulating hormone levels. Until recently, no patients with mutations in THRA had been identified. In an attempt to predict the clinical phenotype of such patients, different TRα1 mutant mouse models have been generated. These mice have a variable phenotype depending on the location and severity of the mutation. Recently, the first humans with mutations in THRA were identified. Their phenotype consists of relatively low serum T4 and high serum T3 levels (and thus an elevated T3/T4 ratio), growth retardation, delayed mental and bone development, and constipation. While, in retrospect, certain features present in humans can also be found in mouse models, the first humans carrying a defect in TRα1 were not suspected of having a THRA gene mutation initially. The current review focuses on the clinical consequences of TRα1 mutations.
Department of Internal Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Alies A
AA
van Mullem
Department of Internal Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Theo J
TJ
Visser
Department of Internal Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Robin P
RP
Peeters
Delayed bone development; Growth retardation; LT4 therapy; Resistance to thyroid hormone; Thyroid hormone receptor α